NBSE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBSE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NeuBase Therapeutics's enterprise value is $-5.82 Mil. NeuBase Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.55 Mil. Therefore, NeuBase Therapeutics's EV-to-EBITDA for today is 0.46.
The historical rank and industry rank for NeuBase Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of NeuBase Therapeutics was 12.66. The lowest was -10.02. And the median was 0.00.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-09-20), NeuBase Therapeutics's stock price is $0.378. NeuBase Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-7.700. Therefore, NeuBase Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for NeuBase Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuBase Therapeutics Annual Data | |||||||||||||||||||||
Trend | Sep12 | Sep13 | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -1.22 | -1.32 | -2.90 | -8.42 | -2.89 |
NeuBase Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 0.13 | 0.18 | 0.08 | 0.32 | 0.32 |
For the Biotechnology subindustry, NeuBase Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NeuBase Therapeutics's EV-to-EBITDA falls into.
NeuBase Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -5.817 | / | -12.552 | |
= | 0.46 |
NeuBase Therapeutics's current Enterprise Value is $-5.82 Mil.
NeuBase Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuBase Therapeutics (NAS:NBSE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NeuBase Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.378 | / | -7.700 | |
= | At Loss |
NeuBase Therapeutics's share price for today is $0.378.
NeuBase Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of NeuBase Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Symetryx Corp | 10 percent owner | 2828 BATHURST ST #400, TORONTO A6 M6B3A7 |
Aleta Shiff | 10 percent owner | 461 LYTTON BLVD., TORONTO A6 M5N 1S5 |
Barry Shiff | 10 percent owner | 461 LYTTON BLVD., TORONTO A6 M5N 1S5 |
William Roland Mann | officer: COO | 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Todd P. Branning | officer: Chief Financial Officer | C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Eric I Richman | director | C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854 |
Eric J Ende | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Sandra Rojas-caro | officer: Chief Medical Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746 |
Kianoush Motesharei | officer: See Remarks | 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Gerald J Mcdougall | director | 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Curt Bradshaw | officer: Chief Scientific Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Gines Diego Miralles | director | 2235 VIA FRESCA, LA JOLLA CA 92037 |
Franklyn G Prendergast | director | |
Dietrich A Stephan | director, 10 percent owner, officer: President and CEO | 213 SMITHFIELD ST, PITTSBURGH PA 15222 |
Lipizzaner Llc | 10 percent owner | 1209 ORANGE STREET, WILMINGTON DE 19801 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 06-11-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By sperokesalga sperokesalga • 02-14-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 05-24-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.